Prostatype Genomics AB (publ) (STO:PROGEN)
Sweden · Delayed Price · Currency is SEK 0.1470
+0.0005 (0.34%)
Sep 4, 2026, 5:29 PM CET
Prostatype Genomics AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1.01 | 0.59 | 1.92 | 3.73 | 0.68 | 2.51 |
| 1.01 | 0.59 | 1.92 | 3.73 | 0.68 | 2.51 | |
Revenue Growth | 208.21% | -69.03% | -48.55% | 445.83% | -72.78% | -16.56% |
Cost of Revenue | 17.95 | 20.8 | 22.36 | 19.83 | 13.49 | 8.49 |
Gross Profit | -16.94 | -20.2 | -20.44 | -16.1 | -12.81 | -5.98 |
Selling, General & Admin | 15.09 | 15.23 | 15.71 | 18.1 | 10.39 | 7.98 |
Research & Development | 1.76 | 1.46 | 2.21 | 3.23 | 3.51 | 1.49 |
Other Operating Expenses | 0.37 | -0.14 | 0.52 | -0.06 | 0.08 | 0.01 |
Operating Expenses | 20.52 | 18.73 | 20.42 | 23.14 | 15.88 | 9.57 |
Operating Income | -37.46 | -38.94 | -40.85 | -39.25 | -28.69 | -15.55 |
Interest Expense | -1.94 | -1.62 | -1.68 | -1.54 | -0.4 | -0.08 |
Interest & Investment Income | 0.09 | 0.09 | 0.04 | 0 | - | - |
Currency Exchange Gain (Loss) | 1.4 | -4.04 | 1.44 | -0.65 | - | - |
Other Non Operating Income (Expenses) | 0 | 0 | 0 | - | -0 | - |
Pretax Income | -37.9 | -44.5 | -41.05 | -41.44 | -29.09 | -15.63 |
Net Income | -37.9 | -44.5 | -41.05 | -41.44 | -29.09 | -15.63 |
Net Income to Common | -37.9 | -44.5 | -41.05 | -41.44 | -29.09 | -15.63 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | - | 34 | 1 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | - | 34 | 1 | 0 | 0 | 0 |
Shares Change | - | 2294.78% | 1645.51% | 343.99% | 28.75% | - |
EPS (Basic) | - | -1.32 | -29.10 | -512.68 | -1597.92 | -1105.51 |
EPS (Diluted) | - | -1.32 | -29.10 | -512.68 | -1597.92 | -1105.51 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -20.96 | -24.06 | -44.99 | -29.21 | -27.69 | -16.08 |
Free Cash Flow Per Share | - | -0.71 | -31.89 | -361.46 | -1521.34 | -1137.23 |
Gross Margin | - | - | - | - | - | -238.34% |
Operating Margin | -3694.18% | -6555.22% | -2130.03% | -1052.76% | -4200.44% | -619.54% |
Profit Margin | -3737.97% | -7492.09% | -2140.30% | -1111.45% | -4258.71% | -622.79% |
Free Cash Flow Margin | -2066.86% | -4050.34% | -2345.88% | -783.61% | -4054.61% | -640.66% |
EBITDA | -35.27 | -36.75 | -38.88 | -39.23 | -28.64 | -15.46 |
D&A For EBITDA | 2.19 | 2.19 | 1.98 | 0.02 | 0.05 | 0.09 |
EBIT | -37.46 | -38.94 | -40.85 | -39.25 | -28.69 | -15.55 |
Revenue as Reported | 1.02 | 0.6 | 1.98 | 3.79 | 0.68 | 2.52 |